R Squared’s Tempest Therapeutics TPST Stock Holding History

R Squared’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15	Closed	-$159	–	1418
2024 Q4	$159	Buy	+15	New	+$194	﹤0.01%	1563

Other funds holding TPST

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

R Squared's TPST Position: Q1 2025 in Review

R Squared sold out of Tempest Therapeutics (TPST) in Q1 2025, closing a stake of 15 shares — an estimated $159 sold.

R Squared first reported a position in TPST in Q4 2024 and held it in 1 quarter. The position peaked at $159 in Q4 2024. 23 funds tracked by Wall St. Rank hold TPST as of Q1 2025.

R Squared reported no remaining Tempest Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 15 Tempest Therapeutics shares in Q1 2025, an estimated $159.
R Squared first reported a position in Tempest Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Tempest Therapeutics position peaked at $159 in Q4 2024.
23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.